

Atrial fibrillation - Pipeline Insight, 2021

<https://marketpublishers.com/r/A387C508C33AEN.html>

Date: May 2021

Pages: 70

Price: US\$ 1,500.00 (Single User License)

ID: A387C508C33AEN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Atrial fibrillation - Pipeline Insight, 2021," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Atrial fibrillation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Atrial fibrillation Understanding

Atrial fibrillation: Overview

Atrial fibrillation (AF or AFib) is the most common irregular heart rhythm that starts in the atria. Instead of the SA node (sinus node) directing the electrical rhythm, many different impulses rapidly fire at once, causing a very fast, chaotic rhythm in the atria. As the electrical impulses are so fast and chaotic, the atria cannot contract and/or squeeze blood effectively into the ventricle. AF is an irregular and often rapid heart rate that occurs when the two upper chambers of the heart experience chaotic electrical signals. The result is a fast and irregular heart rhythm. The heart rate in AF may range from 100 to 175 BPM. The normal range for a heart rate is 60–100 BPM. A major concern with atrial fibrillation is the potential to develop blood clots within the upper chambers of the heart. These blood clots forming in the heart may circulate to other organs and lead to

blocked blood flow (ischemia).

'Atrial fibrillation - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atrial fibrillation pipeline landscape is provided which includes the disease overview and Atrial fibrillation treatment guidelines. The assessment part of the report embraces, in depth Atrial fibrillation commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atrial fibrillation collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Atrial fibrillation R&D. The therapies under development are focused on novel approaches to treat/improve Atrial fibrillation.

Atrial fibrillation Emerging Drugs Chapters

This segment of the Atrial fibrillation report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Atrial fibrillation Emerging Drugs

CKD-825: Chong Kun Dang Pharmaceutical

CKD-825 acts as alpha-1 adrenergic receptor antagonists, alpha-beta-adrenergic receptor antagonists, beta-adrenergic receptor antagonists and calcium channel antagonists. Chong Kun Dang Pharmaceutical is developing CKD-825 for AF. CKD-825 is currently in Phase III stage of development.

Gencaro: ARCA biopharma

Gencaro (bucindolol hydrochloride) is a pharmacologically unique beta-blocker and mild vasodilator in a clinical trial for the treatment and prevention of recurrent AF, or AF, in patients with heart failure with mid-range ejection fraction, or HFmrEF. Gencaro's mechanism of action (MOA) is unique among beta-blockers due to its sympatholytic (norepinephrine lowering) and inverse agonism (inactivation of constitutively active receptors) properties.

AGN-151607: AbbVie

AGN-151607 is an inhibitor of acetylcholine, a modulator of membrane transport protein and acts as neuromuscular blocking agents. It was originally developed by Allergan, but later on, Allergan was acquired by Abbvie. So, currently, Abbvie is developing AGN-151607 and is in the Phase II stage of development for AF.

HBI-3000: HUYA Bioscience International

HBI-3000 is a multi-ion channel blocker with in vitro inhibitory effects on INa-Peak, INa-Late, ICa, L and IKr being developed by HUYA Bioscience International for the conversion of recent-onset AF. The drug's preclinical and clinical pharmacology supports the potential of HBI-3000 to restore sinus rhythm in AF. The drug has demonstrated a low risk for proarrhythmia in preclinical testing.

Further product details are provided in the report

Atrial fibrillation: Therapeutic Assessment

This segment of the report provides insights about the different Atrial fibrillation drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Atrial fibrillation

There are approx. 15+ key companies which are developing the therapies for Atrial fibrillation. The companies which have their Atrial fibrillation drug candidates in the most advanced stage, i.e. phase III include, Chong Kun Dang Pharmaceutical.

Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Atrial fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Nasal

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Anticoagulant

Bacterial proteins

Small molecule

Gene therapy

Cardiovascular therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Atrial fibrillation: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atrial fibrillation therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atrial fibrillation drugs.

Atrial fibrillation Report Insights

Atrial fibrillation Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Atrial fibrillation Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Atrial fibrillation drugs?

How many Atrial fibrillation drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atrial fibrillation?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atrial fibrillation therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Atrial fibrillation and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Chong Kun Dang Pharmaceutical

ARCA Biopharma

AbbVie

HUYA Bioscience International

Merz Pharma

AbbVie

OMEICOS Therapeutics

Acesion Pharma

Milestone Pharmaceuticals

Verseon

Vivasc Therapeutics

Espero BioPharma

Key Products

CKD-825

Gencaro

AGN-151607

HBI-3000

Botulinum Toxin Type A Injection [Xeomin]

AGN-151607

OMT-28

AP30663

Etripamil

VE-1902

CTP-Amio

ESP-001

Contents

Introduction

Executive Summary

Atrial fibrillation: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Atrial fibrillation – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Atrial fibrillation companies' collaborations, Licensing, Acquisition -Deal Value Trends

Atrial fibrillation Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

CKD-825: Chong Kun Dang

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

AGN-151607: AbbVie

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

HBI-3000: HUYA Bioscience

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Atrial fibrillation Key Companies

Atrial fibrillation Key Products

Atrial fibrillation- Unmet Needs

Atrial fibrillation- Market Drivers and Barriers

Atrial fibrillation- Future Perspectives and Conclusion

Atrial fibrillation Analyst Views

Atrial fibrillation Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Atrial fibrillation

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Atrial fibrillation
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Atrial fibrillation - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/A387C508C33AEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A387C508C33AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970